isosorbide-5-mononitrate (Ismo)

01/12/1984 - "The 14-day therapy with elantan 20 in a dosage of 3 X 1 tabl./day showed a cure rate of 79.9% in patients who had already been treated, a complete remission of the angina pectoris attacks being achieved in 50% and a reduction of the frequency of the attacks in a further 29.9%. "
01/01/1986 - "Various studies on the pharmacodynamic and clinical properties of isosorbide-5-mononitrate (IS-5-MN) indicate that this drug is effective in the treatment of stable angina pectoris. "
01/01/1994 - "Controlled-release 5-ISMN 60 mg given once daily was effective in angina pectoris patients for at least 9 h after the dose and showed no clinical signs of tolerance after 2 weeks of the treatment. "
01/01/1994 - "[The efficacy of 2 new drug forms of isosorbide-5-mononitrate in patients with stable stenocardia of effort]."
10/01/1998 - "This study was undertaken to compare the anti-anginal and anti-ischemic efficacy of controlled-release 5-ISMN 60 mg administered once daily and conventional 5-ISMN 20 mg given twice daily in patients with stable angina pectoris. "

02/01/1997 - "Isosorbide-5-mononitrate is also effective in the prevention of bleeding. "
03/01/2011 - "Among 687 patients from six trials comparing EBL with beta-blockers plus isosorbide mononitrate for secondary prevention, there was no effect on either gastrointestinal bleeding (RR 0.95 [95% CI 0.65 to 1.40]) or variceal bleeding (RR 0.89 [95% CI 0.53 to 1.49]). "
10/01/2001 - "The present study evaluates whether isosorbide-5-mononitrate (Is-MN) effectively prevents variceal bleeding in patients with contraindications or who could not tolerate beta-blockers. "
03/01/2011 - "Both EBL and beta-blockers may be considered first-line treatments to prevent first variceal bleeding, whereas betablockers plus isosorbide mononitrate may be the best choice for the prevention of rebleeding."
12/01/2000 - "Particular attention will be devoted to the potential role of the combination therapy of beta-blockers with isosorbide-5-mononitrate for preventing re-bleeding and to the best approach to patients with intolerance or contraindications to beta-blockers. "

03/01/2011 - "The aim of the present study was to evaluate the safety and efficacy of oral sustained-release isosorbide mononitrate on hypertension and LVH in MHD patients. "
03/01/2005 - "Isosorbide mononitrate (ISMN) is effective in the short-term for decreasing systolic blood pressure, pulse pressure, and pulse wave reflection in patients with systolic hypertension. "
05/01/2003 - "The present study aimed to evaluate the CsA effect on the platelet NO-cyclic guanosine-3',5'-monophosphate (cGMP) pathway and the putative benefits of concomitant isosorbide-5-mononitrate (IS-5-MN) administration on CsA-induced hypertension and on platelet hyperactivation. "
12/01/1999 - "A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension."
12/01/2015 - "The role of sustained release isosorbide mononitrate on corticosteroid-induced hypertension in healthy human subjects."

01/01/2004 - "In patients with coronary heart disease with ischaemic episodes the onset of therapeutic activity was more rapid with intravenous ISDN compared to 5-ISMN. "
01/01/2004 - "Twenty-five patients with coronary heart disease were randomly allocated to receive intravenous ISDN or 5-ISMN. "
01/01/2001 - "[Mono Mac 50D treatment results in patients with chronic coronary heart disease]."
08/01/1994 - "The advantage of Olicard 40 was demonstrated, expressed by higher effectiveness in the treatment of coronary heart disease (especially its "silent" form) without development of tachyphylaxis and with lower per cent of adverse reactions."
01/01/1987 - "Thirty-eight male patients with coronary heart disease were treated with 1 capsule Elantan Long (50 mg IS 5-MN) daily over a period of 1 year. "

04/01/2010 - "Histopathologic examination of the livers of CCl(4)-treated rats administered 5-ISMN at 7.2 mg/kg showed marked restoration of the normal architecture of the liver tissue and minimal fibrosis. "
02/01/2003 - "Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis."
04/01/1996 - "We investigated the effects of isosorbide-5-mononitrate (40 mg, orally; n = 12) or placebo (n = 10) on variceal pressure (non-invasive endoscopic gauge) and hepatic haemodynamics in 22 patients with cirrhosis. "
04/01/1996 - "Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis."
01/01/1995 - "Oral isosorbide-5-mononitrate (Is-5-Mn) was given in doses of 10 and 40 mg acutely and chronically (twice daily for four weeks), allowing a nitrate free interval to 25 patients with cirrhosis. "